건선환자에서 Adalimumab 과 Cyclosporine 사용 후 발생한 Follicular Lymphoma = Follicular lymphoma in a psoriasis patient treated with adalimumab followed by cyclosporine

다국어 초록 (Multilingual Abstract)

Biologics and conventional immunosuppressants are widely used for psoriasis. Among them, tumor necrosis factor-α inhibitors and cyclosporine are frequently implicated for moderate to severe plaque psoriasis. However, because of their immunoregulatory effect, both have been suspected to increase the risk of lymphomas, although each drug’s individual effect has never been definitively proven. Of course, little is known about the potential synergistic effect of them on the development of lymphoma.
A 47-year old man, previously diagnosed with psoriasis, was treated with adalimumab for 9 months and received cyclosporine for 6 months thereafter. Three months later, he developed dyspnea and weight loss. Laboratory exam showed markedly elevated white blood cells and multifocal lymphadenopathy and pleural effusion were revealed by imaging studies. Bone marrow and lymph node biopsy confirmed the diagnosis of follicular lymphoma.
Here, we report a case of follicular lymphoma in a patient with psoriasis treated with adalimumab followed by cyclosporine.

참고문헌 (Reference)

1 Cather JC, "Use of biologic agents in combination with other therapies for the treatment of psoriasis" 15 : 467-478, 2014

2 Bewtra M, "Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease" 6 : 621-631, 2010

3 Gelfand JM, "The risk of lymphoma in patients with psoriasis" 126 : 2194-2201, 2006

4 Nalesnik MA, "The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression" 133 : 173-192, 1988

5 Koo JY, "The develop ment of B-cell lymphoma in a patient with psoriasis treated with cyclosporine" 26 : 836-840, 1992

6 Armstrong A, "Safety of ixekizumab treatment for up to 5 Years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000patient-years of exposure" 10 : 133-150, 2020

7 Fiorentino D, "Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry" 77 : 845-854, 2017

8 Yang C, "Risk of lymphoma in patients with inflammatory bowel disease treated with anti-tumour necrosis factor alpha agents: a systematic review and meta-analysis" 12 : 1042-1052, 2018

9 Wong AK, "Risk of lymphoma in patients receiving antitumor necrosis factor therapy : a metaanalysis of published randomized controlled studies" 31 : 631-636, 2012

10 Kaushik SB, "Psoriasis : Which therapy for which patient : psoriasis comorbidities and preferred systemic agents" 80 : 27-40, 2019

11 Yamazaki K, "Primary effusion lymphoma-like lymphoma unrelated to human herpesvirus 8with aggressive clinical course in patient receiving cyclosporine" 31 : e435-e438, 2013

12 Hruska CJ, "Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab" 1 : 56-59, 2015

13 Vaengebjerg S, "Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis" 2020

14 Deodhar A, "Long-term safety of secukinumab in patients with moderate-tosevere plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis : integrated pooled clinical trial and post-marketing surveillance data" 21 : 111-, 2019

15 Dommasch E, "Is there truly a risk of lymphoma from biologic therapies?" 22 : 418-430, 2009

16 Rodriguez AA, "Hodgkin lymphoma following adalimumab for the treatment of Crohn"s disease in an adolescent" 59 : 2403-2405, 2014

17 Masouye I, "B-cell lymphoma after cyclosporine for keratosis lichenoides chronica" 129 : 914-915, 1993

18 Choi JH, "Adverse effects of biological treatment for psoriasis" 3 : 15-22, 2006

19 Karanikolas GN, "Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis : results from a prospective 12-month nonrandomized unblinded clinical trial" 38 : 2466-2474, 2011

20 Burmester GR, "Adalimumab : long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn"s disease" 72 : 517-524, 2013